4//SEC Filing
El-Hibri Fuad 4
Accession 0000899243-20-030866
CIK 0001367644other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 6:30 PM ET
Size
17.5 KB
Accession
0000899243-20-030866
Insider Transaction Report
Form 4
El-Hibri Fuad
DirectorCEO & Chairman10% Owner
Transactions
- Exercise/Conversion
Common Stock
2020-11-09$26.45/sh+20,000$529,000→ 1,143,988 total - Sale
Common Stock
2020-11-09$95.26/sh−20,000$1,905,200→ 1,123,988 total - Exercise/Conversion
Common Stock
2020-11-10$26.45/sh+19,391$512,892→ 1,143,379 total - Sale
Common Stock
2020-11-10$88.21/sh−19,391$1,710,480→ 1,123,988 total - Exercise/Conversion
Stock Options (Right to Buy)
2020-11-09−20,000→ 19,391 totalExercise: $26.45Exp: 2022-03-09→ Common Stock (20,000 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2020-11-10−19,391→ 0 totalExercise: $26.45Exp: 2022-03-09→ Common Stock (19,391 underlying)
Holdings
- 2,140,463(indirect: By Intervac, L.L.C.)
Common Stock
- 1,524,155(indirect: By Biovac, L.L.C.)
Common Stock
Footnotes (6)
- [F1]All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- [F2]The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.85 to $98.49. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.69 to $90.00. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Intervac, L.L.C. ("Intervac") is the direct owner of 2,140,463 shares of the Issuer's common stock. The Reporting Person serves as the managing member of Intervac and the Reporting Person or his wife serve as the trustee of each of the members of Intervac. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- [F5]The Reporting Person, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C., which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- [F6]The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018.
Documents
Issuer
Emergent BioSolutions Inc.
CIK 0001367644
Entity typeother
Related Parties
1- filerCIK 0001380185
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 6:30 PM ET
- Size
- 17.5 KB